Private Advisor Group LLC trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) by 75.4% during the 4th ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

Highlights,The New York State Common Retirement Fund raised its stake in ImmunityBio by 62.8% in the fourth quarter.,Several ...

Fintel reports that on March 6, 2025, HC Wainwright & Co. initiated coverage of ImmunityBio (NasdaqGS:IBRX) with a Buy ...

H.C. Wainwright analyst Andres Maldonado initiated coverage of ImmunityBio (IBRX) with a Buy rating and $8 price target ImmunityBio is a ...

We recently published an article titled Trade Tensions Weigh Heavily on 10 Stocks. In this article, we are going to take a ...

ImmunityBio’s revenue growth was driven by sales of its ANKTIVA therapy following FDA approval in April 2024. The company reported net product revenue of $7.2 million for Q4, representing a 21% ...

ImmunityBio (IBRX) delivered earnings and revenue surprises of 42.31% and 13.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $59.2 million in its fourth quarter. The San Diego-based company said it had a loss of 9 cents per share. Losses ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced certain operational results following approval of the permanent J-c ...

The US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for Anktiva ...

D. Boral Capital reaffirmed their buy rating on shares of ImmunityBio (NASDAQ:IBRX – Free Report) in a research report released on Friday,Benzinga reports. The firm currently has a $30.00 target price ...